%0 Journal Article
%T 浅谈免疫检查点抑制剂联合放化疗治疗局限期小细胞肺癌的研究进展<br>The Research Progress of Immune Checkpoint Inhibitor and Chemoradiotherapy for Limited Stage Small Cell Lung Cancer
%A 红艳
%A 曲洪澜
%J Advances in Clinical Medicine
%P 8145-8150
%@ 2161-8720
%D 2022
%I Hans Publishing
%R 10.12677/ACM.2022.1291173
%X 局限期小细胞肺癌(LS-SCLC)是一种潜在的可治愈疾病。然而，大多数患者在最终治疗后不久出现疾病复发。一线铂/依托泊苷联合免疫疗法治疗大分期小细胞肺癌(SCLC)具有生存效益。因此，重要的是确定免疫治疗对总生存率的提高是否可以更早地转化为LS-SCLC的治疗模式。在这里，我们回顾了放射和免疫治疗联合的潜在临床前期，各自治疗方式的安全性和有效性，以及正在进行的探索LS-SCLC新治疗方法的试验。LS-SCLC的关键试验正在进行，预计将有助于了解免疫疗法与铂基放化疗并行治疗的有效性和安全性。<br />
Limited stage small cell lung cancer (LS-SCLC) is a potentially curable disease. However, most pa-tients develop a disease relapse shortly after the definitive treatment. First-line plati-num/etoposide combined immunotherapy has survival benefits in treating large-stage small-cell lung cancer (SCLC). Therefore, it is important to determine whether the improved overall survival achieved by immunotherapy can translate earlier into treatment modalities for LS-SCLC. Here, we review the potential preclinical phase of the combination of radiation and immunotherapy, the safety and efficacy of the respective treatment modalities, and ongoing trials exploring new thera-pies for LS-SCLC. Key trials of LS-SCLC are ongoing and are expected to help understand the efficacy and safety of immunotherapy treated in parallel with platinum-based chemoradiotherapy.
%K 局限期小细胞肺癌，LS-SCLC型，免疫治疗，同步免疫治疗放化疗<br>Limited Stage Small Cell Lung Cancer
%K LS-SCLC Type
%K Immunotherapy
%K Synchronous Immunotherapy and Chemoradiotherapy
%U http://www.hanspub.org/journal/PaperInformation.aspx?PaperID=55493